Exelixis Inc. (EXEL)
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally
Biotech leader Exelixis stock is attempting to regain a recent buy point during Monday's stock market rally. The post Biotech Leader Exelixis Eyes Buy Point In Monday's Stock Market Rally appeared first on Investor's Business Daily.
Exelixis Growth Continues with Big Money Boosts
Oncology company Exelixis, Inc. (EXEL) growing business, eyeing more.
EXEL or TECH: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Why Exelixis Stock Trounced the Market on Thursday
Cancer drug specialist Exelixis (EXEL 5.02%) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to push its shares 5% higher on the day.
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
On Friday, Exelixis, Inc. EXEL authorized repurchasing up to an additional $500 million of the company's common stock before December 31, 2025.
Is Exelixis (EXEL) a Solid Growth Stock? 3 Reasons to Think "Yes"
Exelixis (EXEL) could produce exceptional returns because of its solid growth attributes.
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
International Markets and Exelixis (EXEL): A Deep Dive for Investors
Explore Exelixis' (EXEL) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
